Compare SSTK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | CAPR |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.9M | 584.9M |
| IPO Year | 2012 | 2011 |
| Metric | SSTK | CAPR |
|---|---|---|
| Price | $4.13 | $7.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $27.00 |
| AVG Volume (30 Days) | 818.0K | ★ 2.5M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 24.14% | N/A |
| EPS Growth | ★ 23.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.76 | $2.96 |
| 52 Week High | $29.50 | $40.37 |
| Indicator | SSTK | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 40.85 |
| Support Level | $3.76 | $7.37 |
| Resistance Level | $6.10 | $10.12 |
| Average True Range (ATR) | 0.26 | 0.55 |
| MACD | 0.08 | -0.10 |
| Stochastic Oscillator | 46.30 | 4.02 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.